Welcome to our dedicated page for Kyowa Hakko news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Hakko stock.
Kyowa Kirin develops and commercializes specialty pharmaceuticals for rare and debilitating diseases, with reported activity in hematology-oncology, rare bone disease, immunology, and other therapeutic areas. News for KYKOY centers on clinical and scientific updates, collaboration activity, medical-conference presentations, and research partnerships tied to the company’s global pharmaceutical business.
Recurring developments include rocatinlimab, an investigational OX40 receptor-targeting T-cell rebalancing therapy studied in the ROCKET Phase 3 program for moderate to severe atopic dermatitis; burosumab research in X-linked hypophosphatemia; and collaboration activity involving ziftomenib in acute leukemias. Coverage also reflects Kyowa Kirin’s industry-academic immunology research relationships and its commercial and development roles across Japan, North America, and global markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kyowa Kirin has appointed Steve Schaefer as the new President of North America, effective April 11, 2023. Schaefer joins from Takeda where he held senior roles, including Senior Vice President of the Neuroscience Business Unit. With over 25 years of experience in the pharmaceutical sector, he has been integral in managing multi-billion dollar commercial portfolios and is known for his expertise in advanced analytics and sales operations.
Schaefer succeeds Gary Zieziula, who is retiring after leading the company through significant growth since April 2020. Under Zieziula's leadership, Kyowa Kirin North America has become the fastest-growing region for the company, contributing over a quarter of global revenues. The transition aims to further enhance Kyowa Kirin's innovative therapies across North America.
Kyowa Kirin Co., Ltd. announces the presentation of Phase 2b study data for rocatinlimab (KHK4083/AMG 451) at the American Academy of Dermatology 2023 Annual Meeting from March 17-22 in New Orleans. The trial involved 274 patients with moderate-to-severe atopic dermatitis, demonstrating significant reductions in serum IgE concentrations and improvements in patient-reported outcomes. Rocatinlimab's IgE reductions were maintained to Week 56. The study's adverse events were similar across groups, with no serious complications reported. Collaborative efforts with Amgen are also highlighted to further develop this potential treatment.
Kyowa Kirin Co., Ltd. announced the presentation of data from its Phase 2b study of rocatinlimab at the American Academy of Dermatology 2023 Annual Meeting on March 17-21 in New Orleans. Rocatinlimab, an investigational anti-OX40 monoclonal antibody, aims to treat moderate-to-severe atopic dermatitis, which affects approximately 15-20% of children and 10% of adults globally. Two posters will be presented, focusing on its efficacy and the reduction of IgE concentrations. Kyowa Kirin has partnered with Amgen for the development and commercialization of rocatinlimab globally, except in Japan, where it retains rights.